Skip to main content

Table 1 Patient characteristics

From: Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer

Number of patients N = 16  
Age   
   Median 59  
   Range 36–73  
Male:female 14:2  
ECOG performance status   
   0 6 37%
   1 8 50%
   2 2 13%
Disease status   
   Primary metastatic 12 75%
   Locally-advanced 4 25%
Prior chemotherapy   
   Uracil-tegafur 4 25%
   5-FU bolus + folinic acid 1 6%
   5-FU + cisplatin 4 25%
   Epirubicin + cisplatin + capecitabine 5 31%
   Epirubicin + doxorubicin + cisplatin 2 13%